



**FOR IMMEDIATE RELEASE**

CONTACT:  
Lea Studer  
SCORR Marketing  
308.237.5567  
[lea@scormarketing.com](mailto:lea@scormarketing.com)

**Camargo Pharmaceutical Services Names Carter Gaither Chief Financial Officer**

**(Cincinnati, Ohio; Feb. 12, 2015)** – [Camargo Pharmaceutical Services](#), the most experienced global strategist in the drug development industry specializing in the 505(b)(2) approval pathway, has named Carter Gaither chief financial officer.

“Carter has been heavily involved in providing financial and operational leadership to emerging and growing companies,” said [Ken Phelps](#), Camargo president and CEO. “He brings Wall Street fundraising experience, which will aid the creation of successful drug development business plans.”

Before joining Camargo, Gaither owned his own management group, which provided accounting, finance, human resources and information technology consulting services including business strategy to small businesses. He also served as managing director of finance and administration for Union Springs, a pharmaceutical startup, and manager of finance and administration for River Cities Capital Funds in Cincinnati.

A certified public accountant, Gaither has deep experiences building robust financial processes for rapidly growing, venture capital backed companies and has been instrumental in developing, implementing and securing investments to fulfill growth strategies.

“We look forward to putting Carter’s financial and strategic expertise to work for our clients,” Phelps added. “Our expertise in the 505(b)(2) approval pathway is in demand by developers around the world seeking to enter the U.S. market. Adding Carter to our team is one more way we are working to make it easier for our global partners to do business with us.”

-more-

**About Camargo Pharmaceutical Services**

Camargo Pharmaceutical Services is the most experienced global strategist providing comprehensive drug development services specialized for the 505(b)(2) approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory and commercial viability of product development opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure FDA buy-in every step of the way. Camargo routinely holds three to six pre-IND meetings a month and works with product developers across more than 25 countries. Connect with Camargo on [LinkedIn](#), read the [company blog](#) and visit [camargopharma.com](http://camargopharma.com) for more information.

###